Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis

Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis, a Randomized Clinical Trial

This study is designed to evaluate whether or not oral viscous budesonide is effective in treating children with Eosinophilic Esophagitis.

Inclusion Criteria:

• Histologic evidence of EE defined as greater than 20 eosinophils per hpf on esophageal biopsy
• Ages 1 yrs and older
• Ability to continue the same diet that the patient was on at the time of EGD with biopsy

Exclusion Criteria:

• Adverse reaction or allergy to budesonide
• Pregnancy
• Chronic diseases requiring immunomodulatory therapy
• Use of swallowed topical corticosteroids for EE within the past 3 months
• Use of systemic steroids 2 months prior to study entry
• Upper gastrointestinal bleed within 4 months of study entry
• Chronic use of medications that predispose to upper gastrointestinal bleeding including non-steroidal anti-inflammatory medications or anticoagulants
• Evidence of adrenal suppression prior to study entry
• Evidence of concurrent eosinophilic gastritis, enteritis, colitis, or proctitis
• Recent changes in asthma or allergic rhinitis therapy for 3 months